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Abstract
Among the very homologous family of K- and L-thionins, known for their antimicrobial activity, the viscotoxin subfamily
differs from other members because it is cytotoxic against tumoral cells but weakly hemolytic. We studied the interactions
between the most active of these toxins, viscotoxin A3 (VA3), and model membranes made of phosphatidylcholine and
phosphatidylserine (PS), the major zwitterionic and acidic phospholipids found in eukaryotic cells. Monolayer studies
showed that electrostatic forces are essential for the interaction and are mainly involved in modulating the embedding of the
toxin in the PS head group region. This in turn induces membrane stiffening, as shown by fluorescence polarization assays
with 1,6-diphenyl-1,3,5-hexatriene and its derivatives. Moreover, vesicle permeabilization analyses showed that there are two
modes of interaction, which are directly related to the stiffening effect and depend on the amount of VA3 bound to the
surface of the vesicles. We propose an interaction model in which the embedding of VA3 in the membrane induces membrane
defects leading to the gradual release of encapsulated dye. When the surfaces of the vesicles are saturated with the viscotoxin,
complete vesicle destabilization is induced which leads to bilayer disruption, all-or-none encapsulated dye release and
rearrangement of the vesicles. ß 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
Previous studies on natural membrane-active pep-
tides have been mainly performed to ¢nd substitutes
to overcome the increasing resistance of pathogenic
bacteria towards antibiotics or antifungal drugs.
However, some of these peptides are toxic to eukary-
otic cells, especially tumoral cells, which means that
they may be of great use for the development of
cancer therapy. It has been shown that the ¢ve
very homologous types of K- and L-thionin have
very di¡erent activities, even though their overall
three-dimensional structure appears to be highly con-
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Abbreviations: CF, 5-(and 6)-carboxy£uorescein; CMC, crit-
ical micellar concentration; DPH, 1,6-diphenyl-1,3,5-hexatriene;
L-DPH-HPC, 2-(3-(diphenylhexatrienyl)propanoyl)-1-hexadode-
canoyl-sn-glycero-3-phosphocholine; EDTA, ethylenediaminete-
traacetic acid; LUVET100, large unilamellar vesicle of 100 nm
diameter obtained by extrusion; MLV, multilamellar vesicle ;
MOPS, 3-(N-morpholino)propanesulfonic acid; NMR, nuclear
magnetic resonance; NPN, N-phenyl-1-naphthylamine; POPC,
1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine; POPS, 1-pal-
mitoyl-2-oleoyl-sn-glycero-3-phospho-L-serine; QELS, quasi-elas-
tic light scattering; TX100, Triton X-100; VA3, viscotoxin A3
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served [1^4]. Type I and II thionins exhibit toxic
e¡ects on Gram-positive and Gram-negative bacteria
and fungi, whereas type III and IV thionins do not
inhibit growth in vitro [5^8]. Interestingly, type I and
II thionins are highly toxic to many mammalian cell
lines [5,7,9]. Viscotoxins, the thionins from mistletoe
(Viscum album), belong to type III and display sim-
ilar toxic activities towards a number of tumor cell
lines [10^12]. The latter membrane-active peptides
are potential anti-cancer drugs.
Although few studies have compared the in vitro
activity of viscotoxins with that of other thionins,
viscotoxins are known to be more toxic to eukaryotic
cells than other thionins. ED50 values measured on
human tumor HeLa cells were in the range of 0.2^1.7
Wg ml31 for viscotoxins [10] and 17 Wg ml31 for the
Pyrularia thionin [13], respectively. Similarly, the in-
cubation of human cultured lymphocytes with 50 Wg
ml31 viscotoxins for 24 h caused some cell death,
whereas no lethal e¡ect was reported for purothionin
[14]. Conversely, viscotoxins are far less hemolytic
than other thionins. Under the same experimental
conditions, 20 Wg ml31 Pyrularia thionin lysed 50%
of human erythrocytes [15,16], whereas 100 Wg ml31
viscotoxin B only caused 10% hemolysis [17]. Visco-
toxin A3 (VA3) (100 Wg ml31) provoked a weak he-
molysis (910%) of rabbit erythrocytes (unpublished
data) whereas Osario e Castro et al. [18] reported that
less than 10 Wg ml31 Pyrularia thionin lysed 21%.
Despite these striking di¡erences, little attention
has been paid to the mechanism of action of visco-
toxins. Studies on thionins suggest that most of their
toxic e¡ects probably result from their direct inter-
action with the cell plasma membrane. Although at-
tempts to isolate speci¢c protein receptors for thio-
nins from di¡erent types of target cells have failed
[15], major changes in the structure of the plasma
membrane have been reported to occur upon inter-
action with thionins [7,9,15,19]. Moreover, there is a
correlation between the toxicity of thionins and their
ability to induce the permeabilization of the target
cells [8]. Results from model membranes strength-
ened this ¢nding [6^8,20^22]. However, the molecu-
lar mechanism behind the toxicity of thionins re-
mains controversial. According to Hughes et al. [7],
thionins create ion channels within the plasma mem-
brane. However, other studies suggest a peptide-in-
duced destabilization of the membrane [8,20].
We studied the interactions between viscotoxin A3
and model membranes. VA3 (KSCCPNTTG10R-
NIYNACRLT20GAPRPTCAKL30SGCKIISGST40-
CPSDYPK), a cationic 46-amino acid peptide iso-
lated from the leaves and stems of European mistle-
toe (V. album, Loranthaceae), is believed to be the
most active of the viscotoxin isoforms [23]. We used
monolayers built from di¡erent phospholipid types
to show that VA3 has a high a⁄nity for acidic phos-
pholipids and to characterize the interaction as a
partial insertion process. Experiments on vesicles
made of 1-palmitoyl-2-oleoyl-sn-glycero-3-phospho-
L-serine (POPS), the major acidic phospholipid of
the eukaryotic plasma membrane, showed that VA3
promotes distinct permeabilizing e¡ects on POPS
vesicles depending on the VA3/POPS ratio. Further-
more, £uorescence polarization measurements pro-
vided some insight into the e¡ects of VA3 on the
overall organization of the lipid bilayer. Finally,
the biological relevance of a proposed interaction
model is discussed.
2. Materials and methods
2.1. Chemicals
POPS and 1-palmitoyl-2-oleoyl-sn-glycero-3-phos-
phocholine (POPC) were purchased from Avanti Po-
lar Lipids (Alabaster, AL, USA). 5-(and 6)-Car-
boxy£uorescein (CF), 1,6-diphenyl-1,3,5-hexatriene
(DPH) and 2-(3-(diphenylhexatrienyl)propanoyl)-1-
hexadodecanoyl-sn-glycero-3-phosphocholine (L-
DPH-HPC) were from Molecular Probes (Eugene,
OR, USA). 3-(N-Morpholino)propanesulfonic acid
(MOPS), sodium azide (NaN3) and Triton X-100
(TX100) were obtained from Fluka (Buchs, Switzer-
land). N-Phenyl-1-naphthylamine (NPN) was pur-
chased from Eastman Kodak (Rochester, NY,
USA). Ethylenediaminetetraacetic acid (EDTA) was
from Sigma-Aldrich (St.-Quentin, France). Other
chemicals were of analytical grade. VA3 was isolated
and puri¢ed from European mistletoe leaves as pre-
viously described [23].
VA3 stock solutions and all other aqueous solu-
tions were gravimetrically prepared with MilliQ
(Millipore) ultrapure water. POPC and POPS were
stored as stock solutions in chloroformic solution
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(CHCl3/MeOH, 9:1, v/v) and POPS was used within
24 h. Lipid purity was routinely controlled by thin
layer chromatography on silica gel plates with
CHCl3/MeOH/H2O (65:25:4, v/v/v) as the eluent.
Phospholipid concentrations were estimated by phos-
phate assay subsequent to total digestion in the pres-
ence of perchloric acid [24].
2.2. Monolayer experiments
Isochoric measurements were performed in a cir-
cular Te£on trough with a 16 cm2 area containing 10
ml subphase (10 mM MOPS, 100 mM NaCl, pH
7.4), by use of a Wilhelmy platinum plate connected
to a home-made electrical torsion balance to measure
the surface pressure. The atmosphere was saturated
with water to prevent evaporation of the subphase
during the experiment and the temperature was
maintained at 21 þ 2‡C. Films with an initial surface
pressure of 10 mN m31 were obtained by successively
depositing the assayed chloroformic lipid solution.
After a lag time of 30 min to allow the evaporation
of the solvent and equilibration of the surface pres-
sure, 10 or 20 Wl of the VA3 aqueous solutions were
introduced below the lipidic monolayer through a
side hole, using a syringe (1 Wl ; Hamilton, Bonaduz,
Switzerland). After 2 min of gentle stirring, another
lag time of 15 min was observed to allow equilibra-
tion. For every 100 Wl of VA3 solution injected, an
equal subphase volume was carefully drawn o¡ to
avoid systematic error measurements of the surface
pressure.
Compression isotherms were obtained as previ-
ously described [25], by use of a laboratory-made
apparatus and a Wilhelmy platinum plate to deter-
mine the surface pressure. Brie£y, about 10 nmoles
of chloroformic lipid solution were carefully depos-
ited on the aqueous phase (10 mM MOPS, 1, 150 or
300 mM NaCl, pH 7.4), to the left of the Te£on
barrier and a 30 min lag time was observed to allow
the solvent to evaporate. One hundred microliters of
a 0.1 mM VA3 solution were then injected under the
lipid monolayer to the right of the Te£on barrier.
After 2 min of gentle stirring and a 30 min lag peri-
od, compression was performed from right to left at
4 Aî 2 min31.
2.3. Preparation of large unilamellar vesicles by
extrusion (LUVET100)
Lipids were solubilized in chloroformic solutions
and the organic solvents were thoroughly removed
¢rst by evaporation under nitrogen and then, over-
night, under vacuum (1 Torr). The dry lipid mixture
was dispersed in the standard bu¡er solution (10 mM
MOPS, 150 mM NaCl, 1 mM EDTA, 0.02% NaN3
(w/v), pH 7.4) to a ¢nal lipid concentration of 1 mg
ml31. After a 30 min lag period to ensure proper
lipid hydration, the mixture was strongly vortexed
for 4 min to obtain multilamellar vesicles (MLV).
LUVET100 were prepared according to the extrusion
method of Hope et al. [26] by use of a mini-extruder
(Avanti Polar Lipids). Brie£y, MLV dispersions were
passed 45 times through two stacked polycarbonate
Fig. 1. Increase in surface pressure upon adding VA3 to the subphase with (R,+) or without (b) a phospholipidic ¢lm at the inter-
face. The ¢lms were made of POPS (R) or POPC (+) and the initial pressure was 10 mN m31.
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¢lters with a pore size of 0.1 Wm. Two drain disks
were placed on both sides of each polycarbonate
membrane. As the £uid to gel phase transition of
POPS occurs at 6^13‡C, both the extrusion proce-
dure and the subsequent vesicle conservation were
performed at room temperature to maintain POPS
in the £uid phase. The size distribution of the vesicles
was checked by quasi-elastic light scattering (QELS)
on a 2C autosizer (Malvern, UK). Between 33 and 45
extrusion cycles, LUVET100 exhibited a monomodal
size distribution with a mean diameter of 106 þ 16
nm.
For £uorescence polarization measurements, DPH
or L-DPH-HPC probes were added to a concentra-
tion of 1% to the chloroformic lipid solution prior to
evaporation under nitrogen. A bu¡er containing ad-
ditional 33.3 mM CF was used for the CF release
assays. Non-encapsulated £uorescent probes were
separated from the vesicles by ¢ltering the vesicles
through a column (19 cmU1.3 cm) of Sephadex G-
50 (Pharmacia) using the standard bu¡er as the elu-
ent. This allowed us to obtain stable POPS vesicles
showing less than 8% CF release over a period of
5 days. In selected experiments, freeze^thaw cycles
were repeated ¢ve times before the extrusion proce-
dure described and results were indistinguishable
from those obtained without freeze^thaw cycles.
2.4. Fluorescence polarization
Fluorescence polarization was measured on a lab-
oratory-made automatic T-format apparatus, as de-
scribed previously [27]. LUVET100 labeled with DPH
or L-DPH-HPC were diluted in standard bu¡er to
obtain a lipid concentration of 25 or 50 WM, that
gave an absorbance value of less than 0.08 at 428
or 452 nm. Di¡erent amounts of VA3 were added
to the LUVET100 suspension and after incubation at
21 þ 2‡C for 10 min with constant stirring, samples
were put in a thermostat controlled housing device
(Peltier unit) so that the temperature of the samples
could be monitored. The temperature was then raised
stepwise from 4 to 22‡C at a rate of 0.5‡C per 3 min.
Fluorescence anisotropy is given by r = (IV+IH)/
(IV+2IH), where I is the £uorescence intensity, and
the subscripts indicate the vertical (V) or horizontal
(H) orientation of the emission polarizer.
2.5. Binding assays
Various amounts of VA3 and LUVET100 in stan-
dard bu¡er, corresponding to di¡erent protein/lipid
molar ratios, were incubated in polycarbonate tubes
(Beckman) with continuous stirring, at 21 þ 2‡C for
20 min. The total volume was 2 ml. Bound and free
proteins were separated by centrifugation (100 000
rpm, 20‡C, 2 h) in a Beckman Optima TLX ultra-
centrifuge, using a TLA-100 rotor. Control experi-
ments showed that less than 5% of the lipids re-
mained in the upper 1.5 ml of the supernatant.
Under the same experimental conditions, VA3 alone
did not appreciably sediment at the bottom of the
tubes but was signi¢cantly adsorbed onto the tube
Fig. 2. Compression isotherms of POPC (A) and POPS (B)
monomolecular ¢lms. These isotherms were recorded without
(F) or with VA3 (0.1 WM) in the subphase, in bu¡ers with dif-
ferent ionic strength modulated by the concentration of NaCl:
1 (b), 150 (R) or 300 mM (+). Each curve is the result of at
least three experiments.
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wall. We thus had to be able to determine the
amount of free toxin, the amount bound to the
LUVET100 and the amount adsorbed on the tube
wall.
To estimate the amount of toxin adsorbed to the
wall, we incubated various amounts of VA3 in poly-
carbonate tubes, but in the absence of LUVET100
and without centrifugation. VA3 samples were
evaporated under nitrogen to eliminate the bu¡er
and their protein content was estimated with the bi-
cinchoninic acid assay (micro-BCA kit, Pierce, Rock-
ford, IL, USA), by measuring the absorbance at 560
nm (A560) on a Perkin-Elmer UV/VIS Lambda 16
spectrometer. In parallel, identical starting amounts
of VA3 were diluted in standard bu¡er and titrated
by the same approach. The ratio of the two corre-
sponding A560 measurements was used to calculate
the fraction of toxin not adsorbed on the tube wall.
The amount of toxin bound to LUVET100 was
estimated as follows. Various amounts of VA3 and
LUVET100 were incubated in parallel with control
tubes containing identical amounts of VA3. After
centrifugation, samples from the assay and control
tubes were concentrated and their protein content
was estimated colorimetrically at 560 nm. The ratio
of the two corresponding A560 measurements was
used to calculate the apparent unbound VA3 frac-
tion. We used the amount of VA3 adsorbed to the
wall to calculate the corrected VA3 fraction bound to
LUVET100.
2.6. CF release assay
Experiments were performed on LUVET100 with
encapsulated CF. The CF release assay is based on
the £uorescence quenching this probe displays at
high concentration [28]. CF release was estimated
£uorometrically by monitoring the decrease in the
self-quenching activity of the probe on an Aminco
SPF 500C spectro£uorometer, with excitation and
emission wavelengths set at 493 and 517 nm, respec-
tively, and a band-pass slit of 2.5 nm.
Kinetic experiments were usually initiated by in-
jecting 5^30 Wl of VA3 stock solutions (0.1 or
1 mM) in a set of 2 ml quartz cuvettes containing
known amounts of lipids (10, 30, 60 and 100 WM). At
a constant temperature of 21 þ 1‡C, the cuvettes were
continuously stirred and shielded from light source
to avoid CF photobleaching. The £uorescence of
each cuvette was periodically monitored over a 50 s
period. The maximum £uorescence was measured by
adding 20 Wl of a 10% (v/v) TX100 solution to each
cuvette. Progress in the release is expressed as the
percentage of CF release (%F) calculated from
[(It3I0)/(Imax3I0)] 100, where It is £uorescence inten-
sity at time t, I0 is background £uorescence of the
Fig. 3. Binding of VA3 on pure POPS LUVET100. The X-axis values were calculated from the wall adsorption curve (insert). Due to
strong wall adsorption no accurate data could be recorded for low VA3 concentrations. The lipid concentrations were 10, 30, 60, and
100 WM. The toxin apparent concentrations were between 1 and 15 WM. An apparent binding a⁄nity 6 3 WM has been estimated.
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vesicles, and Imax is £uorescence measured after the
addition of TX100.
We selected concentrations of lipids and encapsu-
lated CF to ensure the complete release of the dye in
in¢nitely diluted conditions, in order to obtain a lin-
ear relation between the £uorescence intensity and
the free CF concentration. In addition, both the
stability of LUVET100 and the possible photobleach-
ing of the probe were systematically investigated in
all experiments. Under our experimental conditions,
negligible photobleaching of the probe was mea-
sured.
2.7. Mode of dye release
To investigate the mode of the VA3-induced CF
release from LUVET100, the theoretical approach de-
scribed by Weinstein et al. [28] was used. Brie£y,
di¡erent amounts of VA3 were added to 30 WM of
CF-loaded LUVET100 and the CF release was moni-
tored as previously described. After a CF release
W50% was achieved, a 1 ml sample of the mixture
was quickly ¢ltered through the Sephadex G-50 col-
umn as described above, to eliminate the released
dye. We performed a £uorometric analysis of the
vesicle fraction with and without TX100 to estimate
the percentage of £uorescence quenching (%Qr) re-
maining in the vesicles, according to: %Qr = (13I0/
Imax). The residual intravesicular concentration of
CF ([CF]r) was calculated from the standard quench
curve obtained by measuring the £uorescence
quenching of vesicle samples prepared in standard
bu¡er solutions containing 8.3^33.3 mM CF. This
enabled us to calculate the equivalent gradual release
(%Fgr) that would have led to the same results, ac-
cording to: %Fgr = [13([CF]r/33.3). (%Qr/%Qi],
where %Qi is the percentage of £uorescence quench-
ing initially measured in vesicles before the addition
of VA3 (see Appendix for details).
2.8. Light scattering
In addition to the CF release assays, light scatter-
ing was followed on an Aminco SPF 500C spectro-
£uorometer, with excitation and emission wave-
lengths both set at 530 nm and using a band-pass
slit of 2.5 nm.
2.9. Determination of the VA3 critical micellar
concentration (CMC)
The CMC was determined by use of the NPN £uo-
rescence assay described by Rui et al. [29]. A 5 nM
NPN solution in standard bu¡er, prepared from a
stock solution of NPN in 99% EtOH, was stored at
21‡C for 30 min before measuring the emission in-
tensity. To determine the hypothetical CMC, di¡er-
ent concentrations of VA3 (1, 5 and 15 WM) were
added to the NPN solution and the emission inten-
Fig. 4. POPS LUVET100 permeabilization induced by varying
the apparent concentrations of VA3. The total lipid concentra-
tion was 30 WM.
Table 1
Characterization of the two distinct vesicle behaviors depending on the amount of VA3 added
Apparent [VA3]introduced
(WM)
Corrected VA3bound/POPS
(R)
Initial slope of the
CF release curve
Maximal CF releasea
(%)
Light scattering
increaseb
93.0 90.025 gr 6 100 V0
v7.5 v0.070 r 100 ++
The total lipid amount was 30 WM.
aCF release was considered maximal when the release rate became equal to the control rate.
bRecorded after 24 h of incubation with VA3.
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sities were compared to that measured in the absence
of VA3. Fluorescence measurements were monitored
on an Aminco SPF 500C spectro£uorometer. The
excitation wavelength was set at 338 nm with a slit-
width of 4 nm and emission was monitored between
360 and 550 nm with a slitwidth of 5 nm.
3. Results
3.1. Monolayer experiments
3.1.1. Isochoric measurements
Isochoric measurements were carried out to deter-
mine the a⁄nity of VA3, used at bulk concentrations
ranging from 1 nM to 1 WM, for monomolecular
¢lms of POPC and POPS (Fig. 1). At a concentra-
tion of 0.15 WM, VA3 induced a 10 mN m31 increase
in the surface pressure of the POPS monolayers, i.e.
a 100% increase of the initial surface pressure Z0
(Z0 = 10 mN m31). Saturation (200% increase) oc-
curred at a concentration of 0.3 WM VA3. In con-
trast, only a slight ¢lm expansion was measured
when VA3 was added to a POPC monolayer as the
surface pressure increased by 6 80% with 1 WM
VA3. In the absence of phospholipids, VA3 also
weakly a¡ected the water surface tension due to its
amphiphilic nature. However, the extent to which
VA3 interacted with the air^water interface is not
comparable with that measured on phospholipidic
¢lms, thus the a⁄nity of VA3 for the interface essen-
tially depends on its a⁄nity for a lipidic surrounding,
especially an acidic one.
3.1.2. Compression isotherm measurements
To evaluate further the role of electrostatic forces
Table 2
Characterization of VA3-induced vesicle perturbations
Apparent [VA3]introduced
(WM)
Apparent
VA3introduced/PS
CF releasea
(%)
Light scattering
increasea (%)
Corrected [VA3]introduced
(WM)
Corrected VA3/POPS
(R)
1 0.1 40 36 0.7 0.013
3 0.1 49 35 2.3 0.025
6 0.1 51 5 5.1 0.035
10 0.1 53 14 9.0 0.045
7.5 0.25 79 40 6.5 0.070
15 0.5 100 75 13.9 0.081
The dashed line separates two di¡erent sets of experiments, depending on the apparent VA3introduced/POPS ratio.
aRecorded after 24 h of VA3 incubation.
Table 3
Mode of dye release
R CF releasea (%) %Qbr [CF]
c
r (mM) %F
d
gr
0.081 49 0.85 33.3 0
0.070 48 0.83 29.5 14
0.070 70 0.76 24.8 34
0.025 51 0.71 21.8 45
0.013 36 0.77 24.8 33
0 0 0.85 33.3 0
See Section 2 for details.
aRelease recorded before passage of the vesicle suspension
through a Sephadex column.
b%Qr = 13I0/Imax.
cObtained from a standard curve giving %Q as a function of
initial encapsulated CF.
d%Fgr = [13([CF]r/33.3)W(%Qr/0.85)].
Fig. 5. Changes in the £uorescence anisotropy of a DPH probe
incorporated into POPS LUVET100 as a function of tempera-
ture. The anisotropy was measured without VA3 in the bulk
(b), or with VA3 in R ratios of 0.025 (E) 0.070 (a) and 0.081
(O). Assays were carried out in duplicate.
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in the interaction of VA3 with phospholipidic mono-
layers, we monitored the compression isotherms of
POPC and POPS monolayers in the presence of 0.1
WM VA3 at various ionic strengths (Fig. 2). VA3
notably increased the surface pressure of weakly or-
ganized POPC monolayers (apparent phospholipidic
molecular area s 100 Aî 2) (Fig. 2A). By progressively
restricting the monolayer area, this e¡ect disap-
peared, showing that VA3 was being continuously
expelled from the phospholipidic ¢lm. A ¢nal exclu-
sion surface pressure close to 20 mN m31 could be
determined, which corresponds to the minimal pres-
sure of a ¢lm that prevents the insertion of viscotox-
in molecules. Increasing the ionic strength did not
change the ¢nal exclusion surface pressure but it
did increase the distribution of VA3 between the
bulk solvent and the interface at larger apparent
phospholipidic molecular areas. Surprisingly, VA3
was incorporated into weakly organized POPS
monolayers to a similar extent (Fig. 2B). Moreover,
increasing the ionic strength increased this phenom-
enon regardless of the phospholipid used: for both
POPC and POPS ¢lms when the apparent phospho-
lipidic molecular area was 120 Aî 2, the surface pres-
sure rose from 2 mN m31 in the presence of 1 mM
NaCl to 5 mN m31 in the presence of 150 mM NaCl.
Nevertheless, the expulsion pattern of VA3 from
POPS ¢lms was quite di¡erent, depending on the
bulk NaCl concentration. In the presence of 1 mM
NaCl, VA3 was not excluded whereas with 150 mM
NaCl VA3 was progressively excluded when the sur-
face pressure exceeded 24 mN m31. In contrast with
POPC ¢lms, the increase in ionic strength decreased
the ¢nal exclusion surface pressure of the toxin from
POPS monolayers.
In addition, some information can be drawn from
the values determined for the ¢nal exclusion surface
pressure, regarding the possible insertion of VA3 into
phospholipidic bilayers. As the surface pressures
evaluated for vesicles are usually between 25 mN
m31 [30] and 32 mN m31 [31], VA3 cannot insert
into POPC vesicles because the ¢nal exclusion sur-
face pressure was only 20 mN m31. Despite the de-
crease in the ¢nal exclusion surface pressure that
accompanied the increasing ionic strength, the higher
values (v35 mN m31) recorded in POPS monolayers
are consistent with at least the partial insertion of
VA3 into POPS vesicles.
3.2. LUVET100 permeabilization:
e¡ect of the negative charge density
The VA3-induced permeabilization of a set of
POPC LUVET100 containing increasing amounts of
POPS was monitored by carrying out CF release
assays to determine the e¡ects of di¡erent negative
charge densities on the permeabilization process.
While no CF release could be recorded using pure
POPC LUVET100, the CF release readily increased as
the amount of acidic phospholipids composing the
LUVET100 increased (data not shown).
3.3. Interaction with POPS LUVET100
3.3.1. Binding assays
As the VA3-induced permeabilization of vesicles
depends on the interaction of VA3 with POPS, bind-
ing assays were performed on pure POPS LUVET100.
To determine accurately the amount of VA3 bound
to POPS vesicles, the strong adsorption of VA3 on
the tube walls was taken into account. Up to 30% of
the viscotoxin was adsorbed on the walls when a
1 WM solution of VA3 was used (Fig. 3). A similar
behavior has been reported previously for other
plant thionins [20,32]. We paid particular attention
to this adsorption to determine the amount of VA3
actually available for the binding process, i.e. by sub-
Fig. 6. Representation of the possible distributions of VA3 on
vesicles. The distributions are Gaussian. The mean of each dis-
tribution is indicated by equivalent R values. Possible values of
the discrete threshold ratio R* fall in the area delimited by the
dark rectangle. See text for details.
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tracting the amounts adsorbed to the wall from the
added VA3. The resulting corrected POPS
LUVET100-VA3 binding curve (Fig. 3), expressed
as the VA3bound/POPS ratio (R), showed that values
increased and reached saturation point when R was
close to 0.075. These results also re£ect a thermody-
namic equilibrium as similar values were obtained
after 10 min, 20 min, 12 h or 24 h in the same con-
ditions.
3.3.2. E¡ects on bilayer integrity
3.3.2.1. CF release and light scattering stud-
ies. The addition of VA3 to POPS LUVET100
caused a dose-dependent release of CF (Fig. 4),
and induced slow, time-dependent, structural
changes on the LUVET100 as shown by light scatter-
ing measurements. Data dealing with the initial slope
of the CF release curves, the maximum CF release,
and the light scattering changes observed upon re-
lease (Table 1) revealed that the vesicles behave in
two distinct ways depending on the amount of visco-
toxin added.
3.3.2.2. The CF release is directly related to the
amount of VA3 bound on the liposomes. The dose-
dependent release of CF can be interpreted as a sur-
face-dependent mechanism or a bulk concentration-
dependent mechanism. A bulk concentration-depen-
dent mechanism means that a critical bulk concen-
tration of VA3 should result in an equilibrium be-
tween two structural states of VA3 in solution. The
high structural stability displayed by thionins and
viscotoxins in solution [33] means this should result
in an equilibrium between monomeric and oligomeric
states of VA3, the oligomers being more reactive
towards the POPS vesicles. A similar behavior has
already been reported for melittin analogues [34].
However, several lines of evidence argue against
this bulk concentration threshold hypothesis: (i) the
£uorescence characteristics (e.g. an increase in the
£uorescent quantum yield or a blue shift of the max-
imum £uorescence wavelength) of NPN did not
change signi¢cantly in the presence of up to 15 WM
VA3, thus no micellar structures could be formed in
these experimental conditions; (ii) nuclear magnetic
resonance (NMR) studies on VA3 in solution did not
detect any dimeric or oligomeric associations with up
to 2 mM VA3 [4]. To prove that VA3 is unable to
form unorganized aggregates, experiments were per-
formed at a ¢xed apparent VA3/POPS ratio but with
increasing apparent VA3 bulk concentrations. If the
wall adsorption of VA3 is taken into account, both
the CF release and the light scattering changes cor-
relate well with the corrected VA3bound/POPS ratio
(R), whereas no correlation exists with the corrected
bulk VA3 concentration (Table 2). Accordingly, CF
release appears to be R-dependent, i.e. to depend on
the VA3 concentration on the vesicle surface.
3.3.2.3. Mode of dye release. To elucidate the R-
dependent CF release from the POPS vesicles, we
investigated the extent of dye released by LUVET100
exhibiting di¡erent VA3 surface concentrations. As
previously reported by Weinstein et al. [28], dye may
be released from vesicles by either an all-or-none or a
gradual mode. In the former case, the dye is released
as a result of the complete leakage of some vesicles,
whereas in the latter case, the dye gradually leaks
from all of the vesicles. The two modes can be dis-
tinguished by measuring the percentage of quenching
remaining in the vesicles (%Qr) after they have lost a
signi¢cant fraction of the dye. If the release depends
on an all-or-none mode, %Qr remains constant, oth-
erwise, if it depends on an gradual mode, %Qr de-
creases by an amount that can be measured by a
standard quench curve. This standard curve was
also used to calculate the predictable equivalent
gradual release (see Appendix for details). As shown
in Table 3, the CF release was mainly a gradual one
when R90.025, but it followed a strictly all-or-none
mode when R reached 0.081, at least in the experi-
mental conditions resulting in 50% CF release. This
all-or-none mode also accounted for the 50% release
that occurred when R was 0.070. Thus, the mode of
CF release di¡ers according to the R ratio. The tran-
sition from one mode of release to the other occurred
for an R value between 0.025 and 0.070.
However, when R was 0.070, the mode of release
was more complex; it was mainly an all-or-none pro-
cess at the beginning of the interaction and became
more gradual afterwards. In fact, for this R value,
the CF release increased by 22%, which is very sim-
ilar to the 20% increase predicted. This means that
the process involves a time-dependent change from
an all-or-none response to a gradual release.
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3.3.3. POPS LUVET100 £uorescence polarization
The £uorescence polarization of DPH incorpo-
rated in POPS LUVET100 was measured to investi-
gate the e¡ect of VA3 on the overall phospholipid
organization. POPS bilayers usually showed a broad
gel-to-£uid transition at around 8^12‡C but, in the
presence of VA3, three distinct changes occurred
(Fig. 5): (i) the probe in the phospholipidic gel phase
behaved in a more constrained manner, (ii) the co-
operativity of the gel to £uid transition increased,
and (iii) the constraints on the probe in a phospho-
lipidic £uid state increased, although this was highly
dependent on the R ratio value. These changes reveal
that the VA3^lipid complex became more organized.
A similar behavior was observed when L-DPH-HPC
was used as a probe (data not shown), suggesting
that the constraining e¡ect of VA3 readily a¡ects
the hydrophobic core of the phospholipid bilayer.
4. Discussion
4.1. Phenomena involved in the approach and the
insertion of VA3 in POPC and POPS
monolayers
As previously reported for other thionins, our re-
sults show that VA3 has a high a⁄nity for phospho-
lipidic surroundings. This is consistent with the over-
all structural features of this plant toxin, which is
highly amphipathic [4]. As proposed for other thio-
nins [20,22,35], the electropositive character of VA3
(+6) may play an essential role in the interaction
with both model and plasma membranes. However,
the electrostatic component of thionins has been sug-
gested to only participate in the ¢rst step of their
interaction with membranes [5,22]. In this respect,
two major results can be drawn from the analysis
of the compression isotherms shown in Fig. 2:
(i) changes in the surface pressure were induced by
VA3 in the large apparent phospholipidic areas.
These re£ect the a⁄nity of the toxin towards weakly
organized lipid ¢lms. Similarly surface pressure was
increased at higher ionic strengths regardless of the
phospholipid (acidic or zwitterionic) used. Thus, the
electrostatic component of VA3 does not appear to
participate in the bulk^membrane partition process;
(ii) in contrast, the analysis of the ¢nal exclusion
surface pressure of VA3, which is related to the
stability of the toxin in the lipid ¢lm, showed that
VA3 is only e⁄ciently inserted into acidic phospho-
lipid monolayers and that this insertion is destabi-
lized by an increase in the ionic strength. This
strongly suggests that the electrostatic component is
involved in the insertion of VA3 into lipid ¢lms.
Accordingly, we favor a salting out process, due to
the amphipathic nature of the toxin, that allows the
toxin to adsorb to the lipid membrane regardless of
its phospholipid (acidic or zwitterionic) composition.
Further insertion and membrane perturbation can
only take place if the appropriate electrostatic inter-
actions occur. Accordingly, POPC LUVET100 must
contain more than 10% POPS to release signi¢cant
amounts of CF after 10 min in the presence of VA3
(data not shown). Both results are consistent with
previous observations showing that even though thi-
onins bind to egg PC vesicles, no subsequent perme-
abilization could be detected [20].
4.2. The interaction of VA3 with POPS vesicles is
governed by a threshold ratio mechanism
Data obtained from model POPS membranes, i.e.
in which the CF release, light scattering and £uores-
cence polarization changes are induced by VA3, in-
dicate that the vesicles change in a R-dependent way,
in the range between Rn ]0.025:0.07[. When
R9 0.025, only partial CF release occurred and nei-
ther structural changes of vesicles nor an increase in
the DPH anisotropy in the POPS £uid phase could
be detected. Conversely, at higher R values, the CF
release was complete and associated with both struc-
tural modi¢cations of the vesicles and an increased
DPH anisotropy in the POPS £uid phase. Such dose-
dependent changes of DPPG vesicles in the presence
of an K-thionin have been already reported to occur
when the apparent protein^lipid ratio is 0.008 [20].
Pyrularia thionin also induced the aggregation of
DPPG vesicles at an apparent threshold value of
0.1 for the protein^lipid ratio [22], and Thevissen et
al. [8] reported that s 0.2 WM of K-hordothionin are
needed to induce signals that can be recorded by the
black lipid membrane apparatus. However, with the
large range of R values used here, the behavior is not
so clear-cut. This is shown in Table 2, where light
scattering reveals some perturbations when R exceeds
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0.035. Likewise, Table 3 shows that, with the excep-
tion of R = 0.081, it is not possible to describe fully
the CF release, which appears to be mainly but not
exclusively governed by a gradual or an all-or-none
mode of dye release. Nevertheless, we will show that
these observations are more consistent with a thresh-
old ratio hypothesis than with a continuous dose de-
pendence hypothesis.
The change observed in the mode of CF release
when R = 0.070 (Table 3) does not depend on a grad-
ual change in the amount of VA3 bound to vesicles
as this binding was shown to be complete after 10
min of incubation. This implies that in these exper-
imental conditions some vesicles released all of their
dye, i.e. bursting of the lipid bilayer, whereas other
vesicles only displayed a slower enhanced permeabil-
ity. The occurrence of some heterogeneity in the size
or composition of our POPS vesicles could account
for a more speci¢c recognition of a few vesicles by
VA3. Accordingly, we carefully ensured that both the
working POPS solution and the freshly prepared
POPS vesicles were free of lysophospholipids. The
size of POPS liposomes was also checked by QELS
to con¢rm that they were homogeneously distributed
(see Section 2). This means it is unlikely that hetero-
geneity could occur in the POPS vesicle preparations.
If it is assumed that there is both a uniform size
distribution of vesicles and a random distribution of
VA3 on the vesicle surface, this latter distribution
can be described as having a Gaussian distribution
because of the large number of vesicles and the large
average number of bound VA3 [36]. This distribution
is based on the average number of VA3 bound per
vesicle, which is, in turn, related to the R ratio (Fig.
6). As some vesicles are lysed and others remain in-
tact (but display an enhanced permeabilization), it
can be assumed that a minimal number of VA3 mol-
ecules must be bound to one vesicle to trigger all-or-
none leakage [36,37]. This number can be divided by
the number of POPS molecules in a 100 nm diameter
vesicle (if 55 Aî 2 is the molecular area of POPS,
1U105 POPS molecules are estimated to constitute
the 4 nm thick bilayer of a 100 nm vesicle), as a
simple way of estimating a discrete threshold ratio
R*. Given that the measured all-or-none mode dye
release accounted for less than 50% of the total dye
release when R was 0.070 and more than 50% when
R was 0.081 (Table 3), the R* value should be be-
tween 0.070 and 0.081, which corresponds to 7000
(0.070) and 8000 (0.081) VA3 molecules per
LUVET100.
As VA3 molecules are thought to interact with
phospholipid bilayers via two amphipathic adjacent
K-helices [38] with a molecular surface of about 400
Aî 2, one VA3 molecule can cover an area correspond-
ing to seven POPS molecules. As the bilayer is 4 nm
thick, 54% of POPS are estimated to form the outer
lea£et of the POPS vesicle bilayer, so that about 7700
VA3 molecules should totally cover one POPS
vesicle. The calculated R* value (0.077) is in the
range of previously estimated R* values (0.070^
0.081). Accordingly, the total permeabilization of
one POPS vesicle would be directly related to its
complete coverage by VA3 molecules in a mono-
layer. This is similar to what has already been re-
ported for other membrane-active peptides derma-
septin [39] and cecropin [40]. A threshold R* ratio
has been proposed for other peptides, such as mag-
ainin and protegrin [41]. Furthermore, assuming a
¢xed discrete threshold R* value, the all-or-none
contribution to CF release can logically occur for a
wide range of R values, depending on the width of
the VA3 distribution on the POPS vesicles.
4.3. Localization of VA3 in the POPS bilayer
So, VA3 presumably interacts with POPS vesicles
in a ‘carpet-like’ fashion [42]. Nevertheless, it para-
doxically sti¡ens and modi¢es the polymorphism
properties of the POPS bilayer, which is not usually
described for peptides with ‘carpet-like’ interactions
[42,43]. On the contrary, other membrane-active pep-
tides usually enhance the disorder of the gel phase
bilayer, as reported for melittin [44], cardiotoxin [45]
and, to a lesser extent, for magainin [46]. Moreover,
as shown for cardiotoxin, an increase in gel phase
disorder and a decrease in the gel to liquid phase
transition cooperativity are related with the insertion
of the toxin in the vicinity of the phosphate groups
of the phospholipids and are associated with the en-
try of water molecules into the bilayer. Likewise, the
observation of the sti¡ening e¡ect of VA3 on POPS
bilayer gives us an indication on the extent of the
VA3 insertion. The polymorphism properties of
POPS bilayers essentially result from intermolecular
H-bonds due to the three electronegative groups of
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the polar head together with the hydration by water
molecules [47,48]. Moreover, unlike the ammonium,
phosphate and ester groups that participate in inter-
molecular H-bonds and are thus partly responsible
for the phospholipid cohesion [47^50], serine carbox-
ylic groups mainly develop electrostatic repulsions.
MD calculations on the e¡ect of Li on a PS bilayer
showed that the charge screening e¡ect and dehydra-
tion in the vicinity of serine carboxylic groups are
related to an increase of the PS bilayer order [51].
In addition, the removal of water molecules from the
acidic lipid bilayers associated with the stabilization
of the gel phase apparently concerns the hydration
by water from the carboxyl groups of the serine
heads [47]. Furthermore, thionins were shown to re-
duce the amount of water associated with polar
heads of the S49 cell plasma membrane phospholip-
ids and the movement of this water [9]. Conse-
quently, if we assume that the electrostatic compo-
nent mainly accounts for the anchoring of VA3 with
POPS, the resulting sti¡ening of the phospholipid
bilayer presumably arises from either the direct in-
teraction with the carboxylic groups of the serine
heads and/or the movement of water molecules out
of the bilayer.
4.4. Permeabilization of POPS vesicles is due to
bilayer defects
31P-NMR measurements performed on PC:PS
(8:2) vesicles in the presence of Pyrularia thionin
led Gasanov et al. [21] to propose that the thionins
directly interact with some PS molecules which may
lead to non-bilayer-organized local domains and bi-
layer degradation. Likewise, if we consider that VA3
binds POPS vesicles electrostatically and triggers the
sti¡ening of the lipid bilayer, the toxin may be able
to create clusters of motionally restricted lipids in the
bilayer. The occurrence of such peptide-induced clus-
ters is far from unusual in PS phospholipids interact-
ing with basic peptides or proteins [52,53]. The pep-
tide-induced clusters would mimic phospholipids at
temperatures near to the gel to £uid transition tem-
perature, which is characterized by coexisting gel and
£uid lipid domains [54]. It is noteworthy that this
transition temperature is associated with an increase
in permeability [55], as a result of bilayer defects
occurring at the interface of the gel and the £uid
lipid domains [54]. This is consistent with the gradual
release of the dye from POPS vesicles induced by
VA3 below the R* threshold value, which would de-
pend on bilayer defects occurring at interfacial re-
gions of the clusters, rather than on VA3-induced
pores. This mechanism is in agreement with the in-
plane di¡usion model reported by Bechinger [56].
Furthermore, the complete covering of POPS vesicles
by VA3 molecules would result in two opposite ef-
fects: a sti¡ening of the lipid bilayer due to the VA3
layer and Brownian agitation, which tends to £uidify
the bilayer. Similarly, given that both VA3 and
POPS are electrically charged, some lateral repulsion
should occur between peptides at high R ratio values,
whereas basic viscotoxins should compete in recruit-
ing charged lipids in their immediate vicinity [53]. As
a result, the vesicles should display some instability,
which could result in the rupture of bilayers and
further vesicle rearrangements that are partly respon-
sible for the increase in light scattering at high R
ratio values.
4.5. Viscotoxin A3 and eukaryotic cells
To conclude, we will discuss the biological reliabil-
ity of our results obtained on model POPS bilayers,
which require PS molecules to occur on the outer
lea£et of the plasma membrane so that VA3 can
interact with tumor cells and disturb their permeabil-
ity. Although PS, which accounts for 10^15% of total
membrane phospholipids, is usually reported to be
concentrated in the inner lea£et of the lipid bilayer
of erythrocytes [57], some compelling evidence exists
for a di¡erent distribution in other cell types. It has
been shown that 10^20% of PS are present in the
outer lea£et of erythroblasts [58,59] and that up to
10% are in BHK-21 cells [60]. Interestingly, undi¡er-
entiated tumorigenic murine and human cells express
7^8-fold more PS in the outer lea£et than their non-
tumorigenic counterparts [61,62]. These discrepancies
may account for the distinct activity of VA3 towards
erythrocytes and tumor cells. In addition, given that
a eukaryotic plasma membrane contains about
1U108 phospholipid molecules and 10% PS, a simple
calculation shows that if only 0.5% of the PS occurs
on the outer lea£et, the amount of exposed PS is
similar to that on one LUVET100. Moreover, accord-
ing to Schaller et al. [23], cytotoxic activity was mea-
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sured with 1U1037 M VA3 for 1U106 cells, which
gives an apparent molecular ratio (1U103 VA3/1 PS)
2000-fold higher than the highest ratio we used in
this study. Thus, we hypothesize that peptide-in-
duced lipid clusters could occur in the outer lea£et
of the plasma membrane and that they are respon-
sible for further membrane perturbations leading to
cell death. This hypothesis is currently under inves-
tigation in the laboratory.
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Appendix
For 30 WM LUVET100 with CF encapsulated at a
concentration of X mM:
I0;X  nX WiQ;X A1
Imax;X  nX WiD A2
where nX represents the number of molecules of CF
encapsulated in 30 WM LUVET100 containing X mM
CF, I0;X is the line-base £uorescence intensity of 30
WM LUVET100 containing X mM CF, Imax;X is the
£uorescence intensity of 30 WM LUVET100 contain-
ing X mM CF after the addition of TX100, iQ;X is
the average £uorescence intensity of one CF mole-
cule in high concentration (X mM) conditions (this
£uorescence is partially quenched and depends on
the value of X) and iD is the average £uorescence
intensity of one CF molecule in in¢nitely diluted
condition (in this study, this condition was obtained
after the addition of TX100 and was independent of
the value of X).
We always started with LUVET100 containing 33.3
mM CF, thus the percentage released (%F) equals:
%F  I t3I0;33:3
Imax;33:33I0;33:3
A3
where It is the £uorescence intensity recorded at time
t.
If the release is gradual leading to vesicles contain-
ing X mM CF (X6 33.3), we obtain:
I t  I0;X  n33:33nX WiD  I0;X  Imax;33:33Imax;X
A4
Thus, in these conditions, we can calculate the
equivalent gradual release (%Fgr) :
%Fgr 
I0;X=Imax;X   Imax;33:3=Imax;X 313I0;33:3=Imax;X 
13I0;33:3=Imax;33:3 W
Imax;X=Imax;33:3 A5
If all LUVETs100 have the same intravesicular vol-
ume:
Imax;X=Imax;33:3  nXn33:3 
X
33:3
A6
and
I0;33:3=Imax;X  I0;33:3nX WiD 
n33:3WI0;33:3
nX WImax;33:3

33:3
X
WI0;33:3=Imax;33:3 A7
Moreover, according to the de¢nition of the per-
centage of £uorescence quenching remaining in the
vesicles before (%Qi) or after the release has occurred
(%Qr) :
%Qr  I3I0;X=Imax;X A8
%Qi  13I0;33:3=Imax;33:3 A9
Finally, by combining Eq. A5 with Eqs. A6^A9,
we obtain:
%Fgr  13CFr33:3 W
%Qr
%Qi
A10
where [CF]r is the residual concentration of CF in
the vesicles after the release.
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